Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cyclophosphamide + Interferon alpha-2b + SV-BR-1-GM |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Interferon alpha-2b | Intron A | Alfatronol|Alfatronol|interferon alfa-2b|Sch 30500 | ||
SV-BR-1-GM | Bria-IMT | SV-BR-1-GM is a vaccine comprising hormone receptor-negative, ERBB2 (HER2)-positive breast cancer cells engineered to secrete GM-CSF, which may induce an antitumor immune response (PMID: 29867922). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03066947 | Phase Ib/II | Cyclophosphamide + Interferon alpha-2b + SV-BR-1-GM | SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer | Completed | USA | 0 |